Fenwick & West represented Crescendo Bioscience, Inc., a global leader in autoimmune diagnostics, as Patent and IP Diligence counsel in its acquisition by Myriad Genetics, Inc. (NASDAQ: MYGN), one of the leading molecular diagnostic company dedicated to making a difference in patients’ lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence for $270 million.
The Fenwick transaction team included patent attorneys Michael Shuster and Pauline Farmer-Koppenol.